Estradiol: the body's principal estrogen
Estradiol blood testing measures the principal estrogen in the body, estradiol. This steroid hormone is made mainly by the ovaries before menopause, in smaller amounts by the testes, and to a lesser degree by the adrenal glands and body fat through conversion of androgens (aromatization). During pregnancy, the placenta becomes a major source. In the bloodstream, estradiol (E2) circulates mostly attached to carrier proteins such as sex hormone–binding globulin (SHBG) and albumin, with a small free portion that can enter cells and act.
Estradiol is a master regulator of reproductive biology. It fuels growth of ovarian follicles and the uterine lining, coordinates ovulation, and supports vaginal and breast tissues. Beyond reproduction, it helps maintain bone strength, vascular flexibility, brain function, and skin integrity. Because estradiol naturally rises and falls in characteristic patterns, its measurement offers a snapshot of current estrogen activity and the status of the brain–gonad communication system (hypothalamic–pituitary–gonadal axis), as well as overall estrogen balance across sexes.
How estradiol coordinates reproductive and systemic health
Estradiol is the body's most active estrogen. It tunes reproductive cycles, bone remodeling, brain signaling, skin and connective tissue integrity, glucose and fat metabolism, and the way blood vessels and fluids balance themselves. An estradiol test shows how well the brain–ovary/testis axis, liver, and adipose tissue are coordinating these systems.
Reading estradiol across cycle, sex, and life stage
Typical values depend on sex, age, and menstrual phase. In cycling women, levels are lowest just after menstruation, peak around ovulation, and settle to moderate in the luteal phase. Pregnancy drives very high values; after menopause and in most men, values are low and steady. For health, the goal is phase- and age-appropriate values that sit near the middle of the expected range rather than persistently at either extreme.
Low values usually reflect reduced ovarian output or estrogen synthesis—common after menopause, with premature ovarian insufficiency, hypothalamic/pituitary underdrive, or aromatase blockade. In premenopausal women this shows up as irregular or absent cycles, hot flashes, vaginal dryness, lower bone density, and shifts in lipids and insulin sensitivity. In men, very low estradiol (often from low testosterone/aromatization) is linked to bone loss and decreased sexual function. People may notice hot flashes, night sweats, vaginal dryness, low libido, sleep and mood shifts, and progressive bone loss; cycles may stop and fertility falls. In teens, it can delay puberty.
High values usually reflect the ovulatory surge, pregnancy, estrogen‑producing cysts/tumors, increased aromatization (e.g., with higher adiposity), reduced hepatic clearance, or exogenous estrogens. Effects can include breast tenderness, fluid retention, migraines, heavier or irregular bleeding, and—without adequate progesterone—endometrial overgrowth; in men, gynecomastia and impaired fertility. When values are high, they are normal in pregnancy but otherwise can reflect anovulation with unopposed estrogen, estrogen‑producing tumors, obesity‑related aromatization, liver disease, or certain medications. In children, signs of early puberty. Chronically high exposure raises endometrial hyperplasia risk. Very high levels raise thrombotic risk.
Cycle timing, assay, and medication effects
Interpretation depends on cycle day, menopausal status, and pregnancy. Contraceptives or hormone therapy alter levels and binding proteins (SHBG). Liver, thyroid, and renal disease affect metabolism. Immunoassays are less accurate at low concentrations; LC–MS methods are preferred in men and postmenopause. Reference intervals are lab- and phase-specific.
Pairing estradiol with FSH, LH, progesterone, and SHBG
Big picture: estradiol integrates the brain–gonad axis with bone, cardiovascular, metabolic, and neurocognitive health. Interpreting it alongside FSH, LH, progesterone, testosterone, and SHBG helps explain symptoms, fertility patterns, and long‑term risks like osteoporosis and endometrial overgrowth. Being in range suggests adequate, phase‑appropriate estrogenic signaling. In cycling women it supports ovulation and endometrial readiness; in men it reflects balanced aromatization. This stability favors healthy bone turnover, endothelial function, favorable lipids, glucose homeostasis, and cognitive and thermoregulatory steadiness. For women, "within reference ranges" tracks mid‑range for the specific cycle phase; for men, a low but stable adult range is typical.
Putting an estradiol result in context
Estradiol (E2) is the most potent estrogen. The blood test measures circulating estradiol made mainly in the ovaries (and in smaller amounts by testes and peripheral tissues). It signals across the brain–gonadal axis to coordinate reproduction and also shapes bone remodeling, vascular tone, lipid and glucose handling, body temperature, mucosal health, mood, and cognition.
FAQs
It measures estradiol (E2) in blood to assess estrogen status and its effects on mood, energy, fertility, sexual health, bone, and metabolism.
It clarifies hormonal drivers of symptoms, aligns care with life stage, and tracks changes from training, nutrition, stress, therapy, or medication.
Cycling females benefit from testing on consistent cycle days. Males and postmenopausal females should test at consistent times and retest after meaningful changes.
Cycle phase, age, stress, training load, body fat, alcohol, sleep, thyroid status, medications (contraceptives, aromatase inhibitors, testosterone), and nutrition.
Usually no fasting is required. Test at a consistent time of day and cycle phase when relevant.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Rosner, W., Hankinson, S. E., Sluss, P. M., Vesper, H. W., & Wierman, M. E. (2013). Challenges to the measurement of estradiol: An Endocrine Society position statement. The Journal of Clinical Endocrinology & Metabolism, 98(4), 1376-1387. https://doi.org/10.1210/jc.2012-3780
- Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause, 19(4), 387-395. https://doi.org/10.1097/gme.0b013e31824d8f40
- Vesper, H. W., Botelho, J. C., Vidal, M. L., Rahmani, Y., Thienpont, L. M., & Caudill, S. P. (2014). High variability in serum estradiol measurements in men and women. Steroids, 82, 7-13. https://doi.org/10.1016/j.steroids.2013.12.005
- Hammond, G. L. (2016). Plasma steroid-binding proteins: Primary gatekeepers of steroid hormone action. The Journal of Endocrinology, 230(1), R13-R25. https://doi.org/10.1530/JOE-16-0070
- Marques, P., De Sousa Lages, A., Skorupskaite, K., Rozario, K. S., Anderson, R. A., & George, J. T. (2024). Physiology of GnRH and gonadotrophin secretion. In Endotext. MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279070/






































.avif)
